No Image Provided

Evox Therapeutics

VC Funding

Series C £50m+

Healthcare & Biotech Published 19 February 2021

Summary

In a significant market movement during February 2021, Evox Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £69,200,000. Leading the round was Redmile Group.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Redmile Group

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series C prioritised

VC Funding

Scan.com

£67,220,000

Sept 2026

VC Funding

Stream

£67,000,000

Jan 2024

VC Funding

Babylon Health

£24,490,661

May 2020

VC Funding

Ternary Therapeutics

£3,600,000

Mar 2026

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.